Reducing kidney damage caused by cisplatin chemotherapy
Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule
This study is looking for ways to help protect your kidneys from damage that can happen when you receive cisplatin, a common chemotherapy drug for cancer, so that your treatment can be safer and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10809726 on NIH RePORTER |
What this research studies
This research focuses on finding ways to protect the kidneys from damage caused by cisplatin, a common chemotherapy drug used to treat various cancers. The study investigates how cisplatin leads to acute kidney injury and aims to develop strategies to prevent this side effect. By using innovative approaches like rapamycin perfluorocarbon nanoparticles, the research seeks to enhance the body's natural waste clearance processes and reduce inflammation in the kidneys. Patients receiving cisplatin may benefit from these findings, which could lead to safer cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are scheduled to receive cisplatin chemotherapy.
Not a fit: Patients who are not receiving cisplatin or those with pre-existing severe kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of kidney injury in cancer patients undergoing cisplatin treatment.
How similar studies have performed: Other research has shown promise in using similar approaches to mitigate chemotherapy-induced side effects, indicating potential for success in this area.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Pan, Hua — Washington University
- Study coordinator: Pan, Hua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.